In recent trading, Syndax Pharmaceuticals Inc (SNDX) stock price has shown some volatility, fluctuating -27.42% over the last five trades and -20.41% over the past 30 trades. This represents a notable ...

Syndax Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or ...

Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today. The company’s shares closed last ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

US stock futures traded in a mixed fashion Monday, with traders awaiting more corporate earnings as well as speeches from a number of Fed officials. Here are some of the biggest premarket US stock ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...